Want to join the conversation?
Biotechnology pioneer $AMGN said it recorded 17% growth from its in-line brands, including Enbrel, Prolia, XGEVA, Sensipar, Vectibix and Nplate. Together, these brands generated $11Bil. The company stated that its legacy medicines also performed well and these continue to be strong cash flow generators.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.